GENERAL COMMENTS
In this paper, Robinson and colleagues search for bacterial DNA in sarcoidosis biopsies. They conclude that bacterial DNA is present in a percent of samples, including all sarcoid samples from patients with active disease. Regarding the DNA, the extraction step referred to a paper published in a hard-to-reach journal that is not referenced on PubMed (de Sanctis, 2010) . Could the authors find other references or provide some details about what they did in the lab? For instance, what was the DNA extraction procedure used and has this been validated to work for different types of bacterial infections? What were the controls for DNA extraction, to ensure it was neither contaminated nor containing PCR inhibitors? Did they test that this protocol was capable of detecting eg. Mtb DNA from a biopsy of a TB patient or Bartonella DNA from a biopsy of a cat-scratch patient? Regarding the PCR, were the different primers all broad-range, or were primers like hsp65 and rpoB designed to detect only a subset of bacteria? What was the concordance between results obtained with different primers-did the authors detect the same bacteria when using different primers? Which primers were used in the Big Dye Sequencing kit? When obtaining a product by PCR, e.g. using 16s, did the authors clone several amplicons and test that they all gave the same bacterial identification? 
This is an appropriate investigation of the role of microbial DNA in sarcoidosis specimens and a correlation with the clinical outcome of the patient. The methods are sound and the results well-presented. However, there is concern in that the readers are suggesting that the presence of microbial DNA justifies therapeutic intervention with antibiotics. They do not discuss the limitations of molecular analysis, such as the persistence of DNA without evidence of an active infection, thus obviating the need for abx. They also do not provide data regarding non-involved areas of involvement by the host to distinguish involvement from colonization; finally, the use of granulomatous controls would be optimal due to the observation that environmental mycobacteria traffic to the granulomatous inflammation (Cosma and Ramakrishnan).
VERSION 1 -AUTHOR RESPONSE
Reviewer: M. Behr 1. The detailed extraction technique and PCR details have been published previously. So to avoid a lengthy Methods section and to meet the word count limitation, we referenced a prior paper paper where the details are found. Unfortunately I made a slight error in the name of the journal: the title is Infectious Disease in Clinical Practice (not Medicine) which is indexed in Pub Med. The rest of the citation in the biobliography is correct. 2. However, since the reviewer could not locate this paper, we will repeat those details in the revised manuscript, as described by the microbiologist co-author Dr. SenGupta in the Methods section, and he also addressed the issues raised by the reviewer. 3. With regard to the DNA evidence of microorganisms in 2 of the 30 control cancer patient nodes: none of the patients had any evidence of active infectious pulmonary disease nor a history of such disease. A modified Gram stain was negative on those two control nodes and there was no histologic features of granulomatous disease in any of the control lymph nodes. Presumably these 2 control cancer patients have had some subclinical contact with these microorganisms in the past. 4.The two typographical errors were corrected. 5. The organism was M. avium, without the intracellulare--a typographical error on my part. 5. Confidence intervals were added in the Results section. 6. The statement about Tropheryma whippelli was modified. One lab has indeed reported culturing 7 isolates of this organism using their proprietary JNSP ("je ne sais pas") technique where they grow some organism and then identify it by PCR (J Clin Microbiol 2003; 41:3816-38122) . I changed the sentence to reflect the fact that it is quite challenging to culture this particular organism, but it can now be done. 7. The statement that ALL long-term symptomatic sarcoidosis patients had PCR-detectable bacteria is accurate (see the Results section with Long-Term Followup and Table 1 ). This obviously relates only to the patients in this series ...and I am not making a generalized statement about all sarcoidosis patients everywhere.
Reviewer: D. Gupta 1. The title was changed as requested to reflect the research question and not indicate the results as it was written originally. 2. However I believe the reviewer misunderstood a portion of the results: ALL LONG-TERM symptomatic sarcoidosis patients (10 of the total 30 patients) had PCR-detectable bacteria in their lymph nodes. This is easily seen in Table 1 . 3. Some of the PCR-positive sarcoid patients were asymptomatic in our study as well. The point is that ALL of the chronically (long-term) symptomatic patients in our study had PCR evidence of bacteria in their nodes. 3. I geared the discussion to reflect the results of this study and to draw in the results of other studies that all imply an infectious etiology of sarcoidosis. Dr. Gupta in his recent review of this topic (Curr Opin in Pulm Med 2012; 18:506-515 ) presents a more exhaustive review of the literature in this regard but our paper in not intended to be an exhaustive review. 3. I have revised the manuscript to more fully discuss the use of antimicrobial agents to treat sarcoid. We didn't mean to imply that we were the first to suggest using antimicrobial agents in sarcoid. We are only suggesting that a prospective clinical trial is reasonable based on the prior data and our data. Subsequent to submitting this paper to the BJM, the third reviewer W. Drake's own study of antituberculous treatment of cutaneous sarcoid was just published this month in JAMA Derm and will be referenced in the revision, further lending support to the call for a clinical trial in systemic sarcoid patients. 4. Reviewer Dr. Gupta is P.I on an ongoing randomized trial in India treating sarcoidosis patients with anti-tuberculous therapy. I just became aware of this ongoing trial and referenced it in my paper, but no results are available.
Reviewer: W. Drake 1. I have revised the manuscript to further emphasize the fact that the mere presence of microorganisms by PCR does NOT indicate that the organism is causing the active disease. In the original manuscript I indicated this possibility, but in the revision I further emphasized this limitation of molecular studies. It is obvious that the PCR-dected bacteria found in our series and the similar results of dozens of other prior studies may indicate just bacterial colonization in the sarcoid nodes and not causation. But the marked lack of microorganisms in control nodes processed in the same manner by the same labs suggests there may be an active role of the organism in sarcoid causation. 2. We have do not have ready access to granulomatous controls since these are available in very few facilities. Also we do not have access to non-involved tissue from these sarcoid patients for study, especially since this was a retrospective study of archived tissue. 3. We based the suggestion that antibiotic treatment is justified in a trial not only by results of our small study, but emphasized that when viewed in relationship to other multiple prior published studies [such as the reviewer's recently published positive trial of antibiotics in cutaneous sacroid (JAMA Dermatol 2013; 149:1040-9) ], that a prospective antibiotic trial in systemic sarcoidosis is certainly warranted. The message in our study is that the chronic sarcoid patients are the ones who overwhelmingly have bacteria-positive nodes by PCR and perhaps these patients should be focus of any therapeutic trial since the majority of the rest of the sarcoid patients have a self-limited clinical course needing minimal if any treatment. 4. I have appropriately revised the manuscript to briefly discuss in more detail the points brought up by this reviewer.
